Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Roche Exorcizes Torcetrapib’s Ghost: CETP Candidate Starts Phase III

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

If those who do not learn from the past are condemned to repeat it, then Roche’s extensive study of Pfizer’s torcetrapib is the Swiss firm’s attempt to avoid a repeat of the first cholesterol ester transfer protein inhibitor’s performance.

You may also be interested in...

Out Of The Ashes: Roche’s Dalcetrapib Data Suggest Still Hope For CETP Inhibitor Class

Experts see various reasons why Roche’s HDL-raising drug may have failed to demonstrate benefit in the dal-OUTCOMES study, including insufficient potency resulting from only partial CETP inhibition. Final word on the class’ fate likely will not be written until outcomes studies by Merck and Lilly report out in several years.

Phase II Preview For Roche's Dalcetrapib May Give CETP Inhibition A Boost

European Society of Cardiology Congress abstract for small study suggests Roche's dalcetrapib is safe and works on plaque burden.

Merck’s Anacetrapib Debut Many Years Away, Despite Robust Phase III Data

CHICAGO – Merck showed dramatic HDL and LDL cholesterol effects and no safety concerns in the Phase III DEFINE study of anacetrapib, but it is still planning to wait to submit the cholesteryl ester transfer protein (CETP) inhibitor until the conclusion of a major outcomes trial.

Related Content


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts